Information Provided By:
Fly News Breaks for March 3, 2020
FATE
Mar 3, 2020 | 07:14 EDT
Oppenheimer analyst Matthew Biegler raised the firm's price target on Fate Therapeutics to $36 from $27 and keeps an Outperform rating on the shares following the company's Q4 update. Biegler tells investors in a research note that he thinks 2020 is shaping up to be a mission critical year for the company, with multiple opportunities to de-risk its iPSC-derived cell therapy platform.